Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin.

Authors :: Cassaday RD
Marks DI
DeAngelo DJ
Jabbour EJ
Advani AS
O'Brien S
Wang T
Neuhof A
Vandendries E
Kantarjian HM
Stock W
Stelljes M
Source :: British journal of haematology [Br J Haematol] 2020 Nov; Vol. 191 (3), pp. e77-e81. Date of Electronic Publication: 2020 Aug 17.
Publication Year :: 2020

Subjects :: Antineoplastic Agents, Immunological administration & dosage
Antineoplastic Agents, Immunological adverse effects
Combined Modality Therapy
Drug Resistance, Neoplasm
Humans
Inotuzumab Ozogamicin administration & dosage
Inotuzumab Ozogamicin adverse effects
Precursor Cell Lymphoblastic Leukemia-Lymphoma diagnosis
Precursor Cell Lymphoblastic Leukemia-Lymphoma mortality
Prognosis
Recurrence
Remission Induction
Retreatment
Treatment Outcome
Antineoplastic Agents, Immunological therapeutic use
Inotuzumab Ozogamicin therapeutic use
Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy

Full Text Access

Tools